Internal Reference Number: FOI_9015
Date Request Received: 05/11/2025 00:00:00
Date Request Replied To: 19/11/2025 00:00:00
This response was sent via: By Email
Request Summary: Oncology
Request Category: Researcher
| Question Number 1: I have a freedom of information request regarding the treatment of certain types of cancer. Could you please answer the following questions. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: • Atezolizumab (Tecentriq) • Durvalumab (Imfinzi) • Nivolumab (Opdivo) • Pembrolizumab (Keytruda) • Chemotherapy • Radiotherapy • Chemotherapy AND Radiotherapy • Osimertinib | |
| Answer To Question 1: • Atezolizumab (Tecentriq) 0 • Durvalumab (Imfinzi) <5 • Nivolumab (Opdivo) 0 • Pembrolizumab (Keytruda) <5 • Chemotherapy <5 • Radiotherapy- not given at SFT • Chemotherapy AND Radiotherapy- see above • Osimertinib 5 | |
| Question Number 2: How many patients has your trust treated in the last 3 months with Pembrolizumab for stage II Melanoma? | |
| Answer To Question 2: Not treated at this Trust | |
| Question Number 3: How many patients has your Trust treated in total in the past 3 months for • Stage 2 Non-Small Cell Lung Cancer • Stage 3 Non-Small Cell Lung Cancer | |
| Answer To Question 3: • Stage 2 Non-Small Cell Lung Cancer <5 • Stage 3 Non-Small Cell Lung Cancer 6 | |
| Question Number 4: How many Stage 2-3 non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: • Atezolizumab • Pembrolizumab monotherapy • Pembrolizumab with chemotherapy • Nivolumab • Osimertinib • Durvalumab • Chemotherapy • Radiotherapy • Chemotherapy and Radiotherapy | |
| Answer To Question 4: • Atezolizumab 0 • Pembrolizumab monotherapy <5 • Pembrolizumab with chemotherapy <5 • Nivolumab 0 • Osimertinib <5 • Durvalumab <5 • Chemotherapy <5 • Radiotherapy- not given at this Trust • Chemotherapy and Radiotherapy- see above | |
| Question Number 5: How many Stage 2-3 non-small cell lung cancer (NSCLC) patients were treated in the past 3 months following surgery with: • Chemotherapy • Radiotherapy • Chemotherapy + Radiotherapy | |
| Answer To Question 5: • Chemotherapy <5 • Radiotherapy- not given at this Trust • Chemotherapy + Radiotherapy- see above | |
| Question Number 6: How many Stage 2-3 resectable non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: • Durvalumab | |
| Answer To Question 6: • Durvalumab- 0 | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
